Cancer Treatment Centers of America (CTCA) has partnered with WebMD in providing information to assist patients and their loved ones with the fight against cancer diagnosis to caregiver support and more. There are two levels in which CTCA fight against cancer: With advanced options and state-of-the-art technologies, they treat the disease. This is done with radiation, chemotherapy, surgery, and immunotherapy. Also, their experienced clinicians deliver supportive therapies that are evidenced informed to assist patients to manage nausea, pain, fatigue, and more.
With them, patients can maintain their stamina, strength, and life quality. They will be able to get the most out of life with CTCA. In addition to their broad array of options, medical experts, and state-of-the-art technology, CTCA give patients and their loved ones a welcoming environment where they can obtain comprehensive cancer care under one roof. And their graphics show the details of their treatment options for the lung, prostate, colon, breast, skin, integrative, and more.
A Second Opinion with their Clinical Specialists
While others with less knowledge and resources to fight against cancer, patients and their loved ones should get a second opinion by contacting CTCA. They have a deep expertise and technical resources associated with the different stages and types of cancer, and they will confirm a current treatment approach. They know that no two cancers are exactly the same, and thus, require an individualized approach. And with their board-certified medical personnel with advanced expertise and training, they can treat specific cancers in a personalized approach according to the patients’ needs.
Oncotarget is a twice week after week peer-revised open read bio-therapeutic journal reporting research on all parts of oncology and printing sub-sectors on subjects past oncology. The periodical was founded in 2010 and is issued by Impact Journals. The executive editors are Andrei V. Gudkov and Mikhail Blagosklonny (Roswell Park Cancer Institute) (ru).
It is a worldwide, journal concentrating on the diagnostic origin of all cancers. It also focuses on possible targets for treatment and therapy conventions used to enhance the administration of those diagnosed with cancer. Download output styles at Endnote.com.
The journal likewise concentrates on the effect of administration programs and new medical agents and conventions on patient viewpoints. An example of a perceptive is the quality of life, fulfillment, and devotion. This periodical investigates the proof behind innovative and present treatments as far as enhancing results
Also, it significantly seeks to explain their use regarding eventual approval and acknowledgment by the patient and therapeutic services expert.
- It is an open read periodical which implies that the paper is accessible to anybody on the planet to download at no cost straight from the Dove site.
- Although Oncotarget and Therapy gets a substantial number of articles, not like numerous traditional periodicals, the paper cannot be dismissed because of the absence of space. It is an electronic periodical, and there are no restrictions on the size or number of the papers that can be printed.
- The time from proposal to a choice being made on the article may, in numerous periodicals, take a few months. The wait is very frustrating for writers. Oncotarget and Therapy have a faster reversal time than this. Usually, peer evaluation is complete in 5-8 weeks. The editorial manager’s choice takes 3-15 days of this. Hence, it is incredibly uncommon to wait for more than eight weeks for the ultimate decision.
- Many writers have discovered that the peer evaluation’s remarks considerably add to their last papers. Read more about Oncotarget at Business Insider.
Oncotarget gives one substantial advantage like optimizing and an individual co-ordinator for their paper. It additionally offers a discount on the issuing processing expense. The periodical enables one to recuperate the article and creation expenses. It also keeps on providing its content for free to readers.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
Eric Lefkosky is an American entrepreneur who has been part of a variety of successful start-up ventures, most notably the popular e-commerce site, Groupon. Originally from Southfield, Michigan, he attended college at the University of Michigan, where he earned both his undergraduate degree and Juris Doctor. His career began while still in college where he began selling carpets. From there, Mr. Lefkosky purchased sports apparel company with a college friend, Brad Keywell. That business eventually dissolved, but Mr. Lefkosky and Mr. Keywell went on to form a number of businesses together.
Today, Mr. Lefkosky is the co-founder and CEO of Tempus, a technology company that makes patient data more accessible and useful in order to help doctors create personalized treatment plans. In addition to Tempus, he is the co-founder and Managing Director of Lightbank, a venture capital fund, as well as the co-founder and Chairman of Groupon. He is also co founder of Uptake Technologies, a predictive analytics platform. He is the co-founder of Mediaocean, a provider of integrated media procurement technology; Echo Global Logistics, a technology enabled transportation firm; and InnerWorkings, a provider of managed print and promotional products.
Mr. Lefkosky is involved in a variety of philanthropic endeavors including the charitable trust he started with his wife, Elizabeth. The Lefkosky Foundation has a focus on children and is involved in creating programs and initiatives that help to enhance the lives and communities it serves. He and his wife are also part of The Giving Pledge, a campaign which is geared towards encouraging the wealthy people of the world to donate a portion of their wealth to philanthropic foundations.
Mr. Lefkosky is involved in the local community of Chicago and sits on a number of boards. He is the Director and Trustee of the Ann and Robert H. Lurrie Children’s Hospital of Chicago. He serves as a trustee at The Art Institute of Chicago. He is a director at The Museum of Contemporary Art. He is also a Trustee at World Business Chicago. In addition to his esteemed career in start-up ventures, he is also an Adjunct Professor at the University of Chicago and the author of Accelerated Disruption, a book about the impact technology has on business.
About Eric Lefkosky: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/